Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

Phase 2

Active, not recruiting

Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA)

Interventions: Drug: rilzabrutinib

First Posted Date: 2021-08-12

Last Posted Date: 2025-05-21

Lead Sponsor: Sanofi

Target Recruit Count: 22

Registration Number: NCT05002777

Locations: 🇺🇸
University of Southern California_Investigational Site Number: 8400009, Los Angeles, California, United States
🇺🇸
TOI Clinical Research LLC_Santa Ana_Investigational Site Number: 8400006, Santa Ana, California, United States
🇺🇸
The Lundquist Institute_Investigational Site Number: 8400005, Torrance, California, United States

and more 24 locations

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

Phase 4

Completed

Conditions: Chronic Rhinosinusitis With Nasal Polyps
Asthma

Interventions: Drug: Dupilumab
Drug: Omalizumab
Drug: Placebo

First Posted Date: 2021-08-10

Last Posted Date: 2025-01-20

Lead Sponsor: Sanofi

Target Recruit Count: 320

Registration Number: NCT04998604

Locations: 🇺🇸
Rush University Medical Center Site Number : 8400035, Chicago, Illinois, United States
🇺🇸
University of Missouri Health Care - University Hospital Site Number : 8400016, Columbia, Missouri, United States
🇺🇸
Chryaslis Clinical Research Site Number : 8400017, Saint George, Utah, United States

and more 91 locations

Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants

Phase 1

Completed

Conditions: Multiple Sclerosis Healthy Subjects

Interventions: Drug: RIPK1 inhibitor

First Posted Date: 2021-07-29

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 14

Registration Number: NCT04982991

Locations: 🇬🇧
Investigational Site Number :8260001, Harrow, London, City Of, United Kingdom

Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Insulin glargine (U300)

First Posted Date: 2021-07-28

Last Posted Date: 2023-01-31

Lead Sponsor: Sanofi

Target Recruit Count: 228

Registration Number: NCT04980027

Locations: 🇮🇳
Investigational site Number 3560003, Jaipur, India
🇮🇳
Investigational site Number 3560013, Nasik, India

Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women

Phase 1

Completed

Conditions: Breast Cancer
Healthy Volunteers

Interventions: Drug: amcenestrant
Drug: [14C]-SAR439859 microtracer
Drug: [14C]-SAR439859

First Posted Date: 2021-06-25

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 6

Registration Number: NCT04940026

Locations: 🇬🇧
Investigational Site Number 8260001, Nottingham, United Kingdom

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Phase 2

Terminated

Conditions: Pleural Mesothelioma
Non-small Cell Lung Cancer

Interventions: Drug: THOR-707
Drug: Pembrolizumab

First Posted Date: 2021-06-07

Last Posted Date: 2024-10-23

Lead Sponsor: Sanofi

Target Recruit Count: 106

Registration Number: NCT04914897

Locations: 🇮🇹
Investigational Site Number : 3800005, Aviano (PN), Friuli-Venezia Giulia, Italy
🇮🇹
Investigational Site Number : 3800001, Rozzano, Milano, Italy
🇰🇷
Investigational Site Number : 4100001, Seoul, Seoul-teukbyeolsi, Korea, Republic of

and more 32 locations

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Phase 1

Terminated

Conditions: Malignant Melanoma
Squamous Cell Carcinoma of Skin

Interventions: Drug: THOR-707
Drug: Cemiplimab

First Posted Date: 2021-06-04

Last Posted Date: 2025-03-05

Lead Sponsor: Sanofi

Target Recruit Count: 46

Registration Number: NCT04913220

Locations: 🇫🇷
Investigational Site Number : 2500003, Bobigny, France
🇨🇱
Investigational Site Number : 1520006, Antofagasta, Chile
🇦🇺
Investigational Site Number : 0360001, Macquarie University, New South Wales, Australia

and more 21 locations

Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa

Phase 3

Active, not recruiting

Conditions: Glycogen Storage Disease Type II

Interventions: Drug: avalglucosidase alfa

First Posted Date: 2021-06-02

Last Posted Date: 2025-03-13

Lead Sponsor: Sanofi

Target Recruit Count: 17

Registration Number: NCT04910776

Locations: 🇺🇸
Children's Hospitals and Clinics of Minnesota- Site Number : 8400008, Minneapolis, Minnesota, United States
🇺🇸
Stanford Hospital- Site Number : 8400006, Stanford, California, United States
🇺🇸
Advanced Medical Genetics- Site Number : 8400002, Hawthorne, New York, United States

and more 13 locations

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

Phase 2

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: placebo IV
Drug: SAR441344 IV
Drug: placebo SC
Drug: SAR441344 SC
Drug: MRI contrast-enhancing preparations

First Posted Date: 2021-05-10

Last Posted Date: 2024-08-15

Lead Sponsor: Sanofi

Target Recruit Count: 129

Registration Number: NCT04879628

Locations: 🇧🇬
Investigational Site Number : 1000002, Pleven, Bulgaria
🇷🇺
Investigational Site Number : 6430008, Tyumen, Russian Federation
🇷🇺
Investigational Site Number : 6430001, Moscow, Russian Federation

and more 35 locations

Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)

Conditions: Sphingomyelin Lipidosis

First Posted Date: 2021-05-07

Last Posted Date: 2022-09-19

Lead Sponsor: Sanofi

Registration Number: NCT04877132

Home Terms & Conditions Privacy Policy